Sugi Predict

Sugi Predict / Compounds / SCHEMBL1242499

SCHEMBL1242499

SCHEMBL1242499

O=C(O)c1cc2cc(Br)sc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 5/20 0.51
▸ PYGL P06737 1/20 0.46
▸ HPGD P15428 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ SRD5A2 P31213 1/20 0.42
▸ GPR35 Q9HC97 1/20 0.42
▸ NFKB1 P19838 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SMAD3 P84022 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ F7 P08709 1/20 0.39
▸ F3 P13726 1/20 0.39
▸ PIN1 Q13526 1/20 0.39
▸ PDPK1 O15530 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30990237 0.80 XDH (0.50) PYGLKDM4EMAPTHRH4
SCHEMBL1244253 0.78 DAO (0.51) DAOHPGDHSD17B10KDM4EMAPT
SCHEMBL2333675 0.78 DAO (0.51) DAOHPGDHSD17B10KDM4EMAPT
SCHEMBL1243721 0.78 HRH4 (0.56) DAOPYGLHPGDHSD17B10KDM4E
SCHEMBL1244790 0.76 RAB9A (0.50) PYGLHPGDHSD17B10KDM4EMAPT
SCHEMBL6625697 0.75 DAO (0.49) DAOHPGDHSD17B10KDM4EMAPT
SCHEMBL6052859 0.74 DAO (0.47) DAOHPGDHSD17B10KDM4EMAPT
SCHEMBL4055623 0.74 DAO (0.47) DAOHPGDHSD17B10KDM4EMAPT
SCHEMBL13530912 0.73 DAO (0.53) DAOHPGDHSD17B10KDM4EMAPT
SCHEMBL1244150 0.70 DAO (0.53) DAOHPGDHSD17B10KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1088824-B1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PFIZER PROD INC (US) 2004-01-07 — — EP claimed
US-20030195361-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PFIZER INC. 2003-10-16 — — US claimed
US-20020183369-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors DU BOIS DAISY JOE (US) 2002-12-05 — — US claimed
US-6399601-B1 ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS PFIZER INC. 2002-06-04 — — US claimed
EP-1088824-A2 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-04-04 — — EP claimed
WO-2025059081-A1 BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2025-03-20 — — WO disclosed
US-20150050371-A1 Extract Formulations of Rhodamnia Cinerea And Uses Thereof BIOTROPICS MALAYSIA BERHAD (MY) 2015-02-19 — — US disclosed
WO-2013133685-A1 EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF BIOTROPICS MALAYSIA BERHAD (MY) 2013-09-12 — — WO disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 — — US disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 — — US disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 — — US disclosed
CN-101511832-A Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC (US) 2009-08-19 — — CN disclosed
US-20020006946-A1 Tetrazole compounds as thyroid receptor ligands PFIZER INC. 2002-01-17 — — US disclosed
US-20010046958-A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors TREADWAY JUDITH L (US) 2001-11-29 — — US disclosed
US-20010046956-A1 Methods of treating obesity using a neurotensin receptor ligand HADCOCK JOHN R (US) 2001-11-29 — — US disclosed
EP-1157695-A1 Method of treating obesity using a neurotensin receptor ligand Pfizer Products Inc. (US) 2001-11-28 — — EP disclosed
EP-1136071-A2 Use of glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-09-26 — — EP disclosed
EP-1127882-A1 Tetrazole compounds as thyroid receptor ligands Pfizer Products Inc. (US) 2001-08-29 — — EP disclosed
EP-1125580-A2 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-08-22 — — EP disclosed
EP-1088824-A2 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-04-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195361-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PYGL, GYS1, PYGM DAO 1915/4885PYGL 1/4885HPGD 797/4885
US-20010046958-A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors PYGM, GYS1, PYGL DAO 1094/4885PYGL 3/4885HPGD 2615/4885
US-20020006946-A1 Tetrazole compounds as thyroid receptor ligands TSHR, THRA, THRB DAO 1344/4885PYGL 1414/4885HPGD 1957/4885
US-20020183369-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PYGL, PYGM, PYGB DAO 1906/4885PYGL 1/4885HPGD 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.